Evidence map›Paper›PMID 27428377›Full record

ArticlePloS one2016

A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.

Guillermo Villegas, Giulia Calenda, Shweta Ugaonkar, Shimin Zhang, Larisa Kizima, Olga Mizenina, Agegnehu Gettie, James Blanchard, Michael L Cooney, Melissa Robbiani and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.Journal of acquired immune deficiency syndromes (1999) · 2017
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Guillermo VillegasPopulation Council, New York, New York, United States of America.
Giulia CalendaPopulation Council, New York, New York, United States of America.
Shweta UgaonkarPopulation Council, New York, New York, United States of America.
Shimin ZhangPopulation Council, New York, New York, United States of America.
Larisa KizimaPopulation Council, New York, New York, United States of America.
Olga MizeninaPopulation Council, New York, New York, United States of America.
Agegnehu GettieAaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America.
James BlanchardTulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America.
Michael L CooneyPopulation Council, New York, New York, United States of America.
Melissa RobbianiPopulation Council, New York, New York, United States of America.
José A Fernández-RomeroPopulation Council, New York, New York, United States of America.
Thomas M ZydowskyPopulation Council, New York, New York, United States of America.
Natalia TeleshovaPopulation Council, New York, New York, United States of America.
Population Council · USAaron Diamond AIDS Research Center · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancyR21AI098645 · NIAID · POPULATION COUNCIL · PI ROBBIANI, MELISSA J, ZYDOWSKY, THOMAS MICHAEL · 2012 to 2013
$425k
NIAID NIH HHS R21 AI098645NIH HHS P51 OD011104
6 · The paper itself

Abstract

Women need multipurpose prevention products (MPTs) that protect against sexually transmitted infections (STIs) and provide contraception. The Population Council has developed a prototype intravaginal ring (IVR) releasing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (M), zinc acetate (ZA), carrageenan (CG) and levonorgestrel (LNG) (MZCL IVR) to protect against HIV, HSV-2, HPV and unintended pregnancy. Our objective was to evaluate the anti-SHIV-RT activity of MZCL IVR in genital mucosa. First, macaque vaginal tissues were challenged with SHIV-RT in the presence of (i) MIV-150 ± LNG or (ii) vaginal fluids (VF); available from studies completed earlier) collected at various time points post insertion of MZCL and MZC IVRs. Then, (iii) MZCL IVRs (vs. LNG IVRs) were inserted in non-Depo Provera-treated macaques for 24h and VF, genital biopsies, and blood were collected and tissues were challenged with SHIV-RT. Infection was monitored with one step SIV gag qRT-PCR or p27 ELISA. MIV-150 (LCMS/MS, RIA), LNG (RIA) and CG (ELISA) were measured in different compartments. Log-normal generalized mixed linear models were used for analysis. LNG did not affect the anti-SHIV-RT activity of MIV-150 in vitro. MIV-150 in VF from MZC/MZCL IVR-treated macaques inhibited SHIV-RT in vaginal mucosa in a dose-dependent manner (p<0.05). MIV-150 in vaginal tissue from MZCL IVR-treated animals inhibited ex vivo infection relative to baseline (96%; p<0.0001) and post LNG IVR group (90%, p<0.001). No MIV-150 dose-dependent protection was observed, likely because of high MIV-150 concentrations in all vaginal tissue samples. In cervical tissue, MIV-150 inhibited infection vs. baseline (99%; p<0.05). No cervical tissue was available for MIV-150 measurement. Exposure to LNG IVR did not change tissue infection level. These observations support further development of MZCL IVR as a multipurpose prevention technology to improve women's sexual and reproductive health.

Indexed as

AnimalsAnti-Infective AgentsCarrageenanContraceptive Agents, FemaleContraceptive Devices, FemaleDrug CombinationsFemaleHIVLevonorgestrelMacaca mulattaMucous MembranePyridinesReassortant VirusesReverse Transcriptase InhibitorsSimian Immunodeficiency VirusTreatment OutcomeAnti-Infective AgentsCarrageenanContraceptive Agents, FemaleDrug CombinationsLevonorgestrelMIV 150PyridinesReverse Transcriptase InhibitorsUreaZinc Acetate

Identifiers

PMID27428377
PMCPMC4948912
OpenAlexW2504380125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.